Preparation & Measurement Guide

SS-31 50mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a SS-31 50mg vial.

Research use only Educational summary of a commonly documented convention. Not approved for human use.
Vial Size SS-31 50mg
Preparation 2mL bacteriostatic water
Concentration 25mg/mL after preparation
Documented Convention 5-15mg once daily

1. Preparation and Measurement

SS-31 50mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 25mg/mL. On a U-100 syringe, each unit contains 250mcg.

50mg / 2mL = 25mg/mL
1 U-100 unit = 0.01mL = 250mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Period Documented amount Measurement
Weeks 1-2 5mg once daily 0.2mL / 20 units
Weeks 3-4 10mg once daily 0.4mL / 40 units
Weeks 5-8 15mg once daily 0.6mL / 60 units

Vial estimate: One 50mg vial contains approximately 10 administrations at the first listed amount or 3 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • SS-31 50mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

SS-31, also studied as elamipretide, targets mitochondrial membranes and has been evaluated in preclinical models and human trials. Clinical results have been mixed, and trial formulations cannot be assumed equivalent to research material.

SS-31 is not approved for general therapeutic use. The table records a circulated convention and is not a clinical recommendation.

Primary Research and Regulatory References

  1. Elamipretide MMPOWER-3 clinical trial
  2. Elamipretide dose-escalation study
  3. SS-31 mitochondrial mechanism study

Research Materials

Review SS-31 50mg Product Information

← Back to Dosage Protocols

Research-use disclaimer: SS-31 50mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.